OXiGENE appoints Kollins to business development post

March 15, 2007

Waltham, MA-OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company.

Waltham, MA-OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company.

Kollins has nearly 20 years of pharmaceutical and biotechnology industry experience, specifically in strategic marketing, new product development, and business development. He also has significant experience working with investors and most recently served as an independent consultant to a health-care-focused investment fund as well as several public and private biopharmaceutical companies.